Leukotrienes, allergy and inflammation.
Immunological and non-immunological injury induce as a result of the action of the enzyme lipoxygenase the release of a series of arachidonic acid metabolites known as leukotrienes. The leukotrienes play an important role in allergic and inflammatory disease. Leukotrienes C4, D4 and E4 which recently have been recognized as constituents of the allergic mediator slow reacting substance of anaphylaxis (SRS-A) induce powerful bronchoconstriction, plasma exudation and weal and flare responses. Leukotriene B4 is involved in the regulation of chemotaxis, chemokinesis and other aspects of both cellular and vascular inflammation. The development of specific lipoxygenase inhibitors may lead to a new class of drugs for the treatment of bronchial asthma and chronic inflammatory diseases.
D001095:Arachidonic Acids / Q000502:physiology*; D001249:Asthma / Q000188:drug therapy / Q000209:etiology; D001711:Biotransformation; D002634:Chemotaxis, Leukocyte; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy / Q000209:etiology*; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology*; D017572:Leukotriene A4; D007975:Leukotriene B4 / Q000502:physiology; D017999:Leukotriene E4; D008084:Lipoxygenase / Q000378:metabolism*; D016859:Lipoxygenase Inhibitors; D009504:Neutrophils / Q000502:physiology; D013189:SRS-A / Q000031:analogs & derivatives / Q000502:physiology*
D001095:Arachidonic Acids; D017572:Leukotriene A4; D016859:Lipoxygenase Inhibitors; D013189:SRS-A; D007975:Leukotriene B4; D017999:Leukotriene E4; D008084:Lipoxygenase